AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16778330 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-ECG monitoring device
Number of subjects: 293
Study 16778330 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable device (TM2425)
Number of subjects: 293
Study 15357561 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4)
Number of subjects: 12
Study 11053725 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypertrophic cardiomyopathy (HC)
Number of subjects: 0
Study 11053725 — intervention group
Group type: COMPARATOR
Intervention: Patients with idiopathic dilated cardiomyopathy (IDC)
Number of subjects: 0
Study 8780630 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-RT group (cisplatin and vinblastine followed by radiation therapy)
Number of subjects: 155
Study 8780630 — intervention group
Group type: COMPARATOR
Intervention: RT group (radiation therapy alone)
Number of subjects: 155
Study 8780630 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-RT group
Number of subjects: 155
Study 8780630 — intervention group
Group type: COMPARATOR
Intervention: RT group
Number of subjects: 155
Study 1595797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg, three times daily)
Number of subjects: 11
Study 1595797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3938014 — intervention group
Group type: EXPERIMENTAL
Intervention: RMSF cases (n=16)
Number of subjects: 26
Study 3938014 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=10)
Number of subjects: 26
Study 3938014 — intervention group
Group type: EXPERIMENTAL
Intervention: RMSF cases (n=8, identified by direct fluorescent antibody technique)
Number of subjects: 26
Study 31607547 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS
Number of subjects: 45
Study 31607547 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS + RE
Number of subjects: 45
Study 31607547 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS + AE
Number of subjects: 45
Study 31628016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour Treating Fields (TTFields) at a frequency of 150 kHz delivered to the thorax in combination with intravenous pemetrexed (500 mg/m2 on day 1) and either cisplatin (75 mg/m2 on day 1) or carboplatin (AUC 5 on day 1) every 21 days for up to six cycles.
Number of subjects: 80
Study 31628016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour Treating Fields (TTFields) as maintenance treatment after chemotherapy.
Number of subjects: 80
Study 31628016 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed and platinum) without TTFields.
Number of subjects: 80
Study 28407637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression
Number of subjects: 21
Study 28407637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Number of subjects: 21
Study 28407637 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 24135239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobe-specific mediastinal lymphadenectomy (LL)
Number of subjects: 96
Study 24135239 — intervention group
Group type: COMPARATOR
Intervention: Systematic mediastinal lymphadenectomy (SL)
Number of subjects: 96
Study 24135239 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LL and SL
Number of subjects: 96
Study 21294116 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Spiritual Strength (BSS) intervention
Number of subjects: 54
Study 21294116 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 54
Study 19826471 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of regretful outcomes in another individual
Number of subjects: 0
Study 19826471 — intervention group
Group type: COMPARATOR
Intervention: First-person experience of regret
Number of subjects: 0
Study 16845694 — intervention group
Group type: EXPERIMENTAL
Intervention: wIRA irradiation
Number of subjects: 111
Study 14678128 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI pacing (80 beats/min)
Number of subjects: 28
Study 14678128 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing (minimum rate 80 beats/min)
Number of subjects: 28
Study 14678128 — intervention group
Group type: EXPERIMENTAL
Intervention: DDI pacing
Number of subjects: 28
Study 14678128 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 28
Study 14678128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate responsive mode (RR-ON)
Number of subjects: 28
Study 14678128 — intervention group
Group type: COMPARATOR
Intervention: Rate responsive mode (RR-OFF)
Number of subjects: 28
Study 11177415 — intervention group
Group type: EXPERIMENTAL
Intervention: True memories
Number of subjects: 0
Study 11177415 — intervention group
Group type: EXPERIMENTAL
Intervention: False memories
Number of subjects: 0
Study 11177415 — intervention group
Group type: COMPARATOR
Intervention: Left hemifield presentation
Number of subjects: 0
Study 11177415 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal slow wave activity
Number of subjects: 0
Study 9375535 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handled (levered) shovel
Number of subjects: 10
Study 9375535 — intervention group
Group type: COMPARATOR
Intervention: Conventional shovel
Number of subjects: 10
Study 1587408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cerulein at doses of 30-60 ng/kg.h
Number of subjects: 16
Study 1587408 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg.h loxiglumide with cerulein
Number of subjects: 16
Study 1587408 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-kcal solid/liquid meal
Number of subjects: 16
Study 1587408 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg.h loxiglumide with a meal
Number of subjects: 16
Study 1587408 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide alone
Number of subjects: 16
Study 3884409 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide tablet
Number of subjects: 40
Study 3884409 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release piretanide
Number of subjects: 40
Study 3884409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 40
Study 31439069 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game
Number of subjects: 204
Study 30055710 — intervention group
Group type: EXPERIMENTAL
Intervention: Out‐of‐School Nutrition and Physical Activity intervention
Number of subjects: 400
Study 26802004 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFI: STD‐related cognitive plus fear appeal imagery approach
Number of subjects: 396
Study 26802004 — intervention group
Group type: EXPERIMENTAL
Intervention: SC: STD‐related cognitive approach
Number of subjects: 396
Study 26802004 — intervention group
Group type: COMPARATOR
Intervention: Control: HIV‐related information based approach
Number of subjects: 396
Study 25074984 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-enanthate (TE) 125 mg/wk
Number of subjects: 60
Study 25074984 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 mg/day)
Number of subjects: 60
Study 25074984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23095425 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylphenidate stimulant medication
Number of subjects: 7
Study 23095425 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of a more difficult PERMP
Number of subjects: 7
Study 20124887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (targeting normoglycemia, between 4.4 and 6.1 mmol/L)
Number of subjects: 2748
Study 20124887 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (infusing insulin when blood glucose levels were >12 mmol/L and stopping at 10 mmol/L)
Number of subjects: 2748
Study 17393164 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel at a dose of 100 mg/m2 followed by carboplatin AUC 2, administered in blocks of six cycles with treatment-free intervals.
Number of subjects: 129
Study 16096324 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy prior to IVF
Number of subjects: 95
Study 16096324 — intervention group
Group type: COMPARATOR
Intervention: Optional salpingectomy after a failed cycle
Number of subjects: 95
Study 12469706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) plus bisphosphonate
Number of subjects: 0
Study 12469706 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus selective estrogen receptor modulator
Number of subjects: 0
Study 12469706 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) monotherapy
Number of subjects: 0
Study 12469706 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus PTH
Number of subjects: 0
Study 12469706 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT alone or in combination with bisphosphonate or PTH
Number of subjects: 0
Study 10603129 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged prednisolone treatment (16 weeks)
Number of subjects: 45
Study 10603129 — intervention group
Group type: COMPARATOR
Intervention: Standard prednisolone treatment (8 weeks)
Number of subjects: 45
Study 8943890 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic irradiation
Number of subjects: 229
Study 8943890 — intervention group
Group type: COMPARATOR
Intervention: No splenic irradiation
Number of subjects: 229
Study 1770568 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous pethidine infusion (100 mg.24 h‐1)
Number of subjects: 20
Study 1770568 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural pethidine infusion (100 mg.24 h‐1)
Number of subjects: 20
Study 6812407 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 27
Study 6812407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 27
Study 6812407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29176388 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline Malate (8 g)
Number of subjects: 12
Study 29176388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29176388 — intervention group
Group type: COMPARATOR
Intervention: Control (no drink mixture)
Number of subjects: 12
Study 28718101 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain laryngeal mask
Number of subjects: 88
Study 28718101 — intervention group
Group type: COMPARATOR
Intervention: Slit Guedel tube
Number of subjects: 88
Study 25825944 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual uFSH (75 U, 3 times a week) and hCG (2000 U, twice a week)
Number of subjects: 67
Study 25825944 — intervention group
Group type: COMPARATOR
Intervention: Sequential uFSH (75 U, 3 times a week every other 3 months) and hCG (2000 U, twice a week)
Number of subjects: 67
Study 24393576 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation with documented pulmonary vein isolation
Number of subjects: 82
Study 24393576 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation without antiarrhythmic drug therapy
Number of subjects: 82
Study 24393576 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologically successful ablation
Number of subjects: 82
Study 21236648 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Tryptophan Depletion (ATD) diet
Number of subjects: 11
Study 21236648 — intervention group
Group type: COMPARATOR
Intervention: Control, balanced diet
Number of subjects: 11
Study 19265599 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended drugs
Number of subjects: 0
Study 19265599 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs only to be used in special circumstances
Number of subjects: 0
Study 19265599 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs which should not be used in normal circumstances
Number of subjects: 0
Study 17701882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg daily for 12 weeks
Number of subjects: 69
Study 17701882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15185523 — intervention group
Group type: EXPERIMENTAL
Intervention: Urostim and antibiotic
Number of subjects: 46
Study 15185523 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic only
Number of subjects: 46
Study 11817871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemex Rx
Number of subjects: 47
Study 11817871 — intervention group
Group type: COMPARATOR
Intervention: Palacos R
Number of subjects: 47
Study 9563668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin
Number of subjects: 102
Study 9563668 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactamase stable antibiotic
Number of subjects: 102
Study 8206773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking cessation intervention (three structured sessions during hospitalization, followed by weekly phone calls for 5 weeks after discharge)
Number of subjects: 80
Study 8206773 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study 8206773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking cessation intervention (specific to cardiovascular unit)
Number of subjects: 80
Study 8206773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking cessation intervention (specific to oncology unit)
Number of subjects: 80
Study 8206773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking cessation intervention (specific to general surgical unit)
Number of subjects: 80
Study 8206773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking cessation intervention (regardless of group assignment)
Number of subjects: 80
Study 3207608 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) with or without radiotherapy (RT)
Number of subjects: 1996
Study 3207608 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 1996
Study 3207608 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 1996
Study 3207608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (CT, RT, or both)
Number of subjects: 1996
Study 29459462 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG+medical therapy (MED)
Number of subjects: 1212
Study 29459462 — intervention group
Group type: COMPARATOR
Intervention: MED alone
Number of subjects: 1212
Study 29459462 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212
Study 28885964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia at moderate altitude (7,000 feet)
Number of subjects: 36
Study 28885964 — intervention group
Group type: COMPARATOR
Intervention: Control (normal conditions)
Number of subjects: 36
Study 26316013 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID‐3
Number of subjects: 100
Study 26316013 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI
Number of subjects: 100
Study 23506125 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO (companion robot)
Number of subjects: 18
Study 23506125 — intervention group
Group type: COMPARATOR
Intervention: Reading group (control)
Number of subjects: 18
Study 21380967 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training (HIS)
Number of subjects: 32
Study 21380967 — intervention group
Group type: COMPARATOR
Intervention: Control class (no intervention)
Number of subjects: 32
Study 18463831 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided antibiotic therapy (duration: 5.9±1.7 days)
Number of subjects: 110
Study 18463831 — intervention group
Group type: COMPARATOR
Intervention: Standardized duration of antibiotic therapy (control group, duration: 7.9±0.5 days)
Number of subjects: 110
Study 16512971 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol/remifentanil (0.5‐1.0 microg kg(‐1) min(‐1))
Number of subjects: 50
Study 16512971 — intervention group
Group type: COMPARATOR
Intervention: propofol/sufentanil (30‐40 ng kg(‐1) min(‐1))
Number of subjects: 50
Study 12800864 — intervention group
Group type: EXPERIMENTAL
Intervention: sport-specific resistance training
Number of subjects: 14
Study 12800864 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 14
Study 11140218 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 9033890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin/gentamicin
Number of subjects: 202
Study 9033890 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone/neomycin
Number of subjects: 202
Study 2060559 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1.0 g
Number of subjects: 12
Study 2060559 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1.0 g plus codeine 60 mg
Number of subjects: 12
Study 6197558 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsidan
Number of subjects: 0
Study 6197558 — intervention group
Group type: EXPERIMENTAL
Intervention: Novocainamide
Number of subjects: 0
Study 6197558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4028621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 25 mg doxepin hydrochloride
Number of subjects: 5
Study 4028621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 600 mg ibuprofen
Number of subjects: 5
Study 4028621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 50 mg indomethacin
Number of subjects: 5
Study 4028621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of 975 mg aspirin
Number of subjects: 5
Study 4028621 — intervention group
Group type: COMPARATOR
Intervention: Aqueous methyl nicotinate (0, 0.1, 1.0, 10.0, and 100 mmol/L) with oral pretreatment of lactose placebo
Number of subjects: 5
Study 29688502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide 0.5 mg once weekly
Number of subjects: 397
Study 29688502 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide 1.0 mg once weekly
Number of subjects: 397
Study 29688502 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched placebo
Number of subjects: 397
Study 26487153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction group (arm abducted at 90°)
Number of subjects: 481
Study 26487153 — intervention group
Group type: COMPARATOR
Intervention: Neutral group (arms kept by the side)
Number of subjects: 481
Study 26487153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction group
Number of subjects: 481
Study 26487153 — intervention group
Group type: COMPARATOR
Intervention: Neutral group
Number of subjects: 481
Study 26487153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 481
Study 25461372 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 302
Study 25461372 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 302
Study 25461372 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 302
Study 22571200 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR-R (melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance)
Number of subjects: 459
Study 22571200 — intervention group
Group type: COMPARATOR
Intervention: MPR (melphalan-prednisone-lenalidomide)
Number of subjects: 459
Study 22571200 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan-prednisone)
Number of subjects: 459
Study 22571200 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR-R
Number of subjects: 459
Study 22571200 — intervention group
Group type: COMPARATOR
Intervention: MPR
Number of subjects: 459
Study 22571200 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 459
Study 20505674 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg once a day, titrated to 16 mg after 1 month
Number of subjects: 194
Study 20505674 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 10 mg once a day, titrated to 20 mg after 1 month
Number of subjects: 194
Study 20505674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 194
Study 18249508 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG)
Number of subjects: 19
Study 18249508 — intervention group
Group type: COMPARATOR
Intervention: Intervention aimed at academic achievement
Number of subjects: 19
Study 18249508 — intervention group
Group type: COMPARATOR
Intervention: Standard program of the school system
Number of subjects: 19
Study 15720844 — intervention group
Group type: EXPERIMENTAL
Intervention: FP strategy (history and examination) on Day 1
Number of subjects: 200
Study 15720844 — intervention group
Group type: COMPARATOR
Intervention: GUM strategy (near-patient microscopy) on Day 1
Number of subjects: 200
Study 15720844 — intervention group
Group type: EXPERIMENTAL
Intervention: GUM strategy (near-patient microscopy) on Day 7
Number of subjects: 200
Study 15720844 — intervention group
Group type: COMPARATOR
Intervention: FP strategy (history and examination) on Day 7
Number of subjects: 200
Study 12627985 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 0
Study 12627985 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 400 mg/day
Number of subjects: 0
Study 12627985 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine 500 mg/day
Number of subjects: 0
Study 10534795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough threshold measured with citric acid aerosols
Number of subjects: 44
Study 10534795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough threshold in smokers with SCI
Number of subjects: 44
Study 10534795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough threshold in smokers without SCI
Number of subjects: 44
Study 8739928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran infusion (7 ml/kg)
Number of subjects: 26
Study 8739928 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 26
Study 1873454 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (one single counselling session and a brief handout on quitting techniques)
Number of subjects: 923
Study 1873454 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated counselling (reinforcing sessions at Months 1, 3, 6, and 9)
Number of subjects: 923